AnchorDx Enrolls the First Patient For Its UriFind® Bladder Cancer Assay Clinical Trial in the U.S.
- Written by PR Newswire
![]() |
GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind®bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in the targeted patients. This prospective,...















